12th mayo 2022
Últimas noticias
Encuentre cualquiera de nuestros más recientes comunicados de prensa, manténgase actualizado con las últimas noticias e infórmese sobre los próximos eventos a los que acudirá Curium.
3rd mayo 2022
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
19th abril 2022
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity
5th abril 2022
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
25th enero 2022
Curium to become major player in the supply on non carrier added Lu-177
6th enero 2022
Curium is attending these global congresses in 2022
15th diciembre 2021
Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer
27th octubre 2021
Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
24th agosto 2021
Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T
1st junio 2021
Curium Acquires Austrian Radiopharmaceuticals Company IASON
5th mayo 2021
RadioMedix & Curium Announce Detectnet™ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®
4th mayo 2021
Curium Announces Filing of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
28th abril 2021
Curium to Expand Noblesville Facility’s Workforce
23rd marzo 2021
RadioMedix & Curium Announce Simplified Coding for Detectnet™ (copper Cu 64 dotatate injection)
17th marzo 2021
A statement on the use of Xenon Xe 133 Gas during the COVID-19 pandemic
2nd marzo 2021
Eckert & Ziegler’s GalliaPharm® distributed by Curium in France
2nd febrero 2021
Curium is attending these global congresses in 2021
26th enero 2021
RadioMedix & Curium Announce Permanent HCPCS Code for Detectnet™ (copper Cu 64 dotatate injection)
9th diciembre 2020
RadioMedix & Curium Announce CMS Transitional Pass-Through Status for Detectnet™ (copper Cu 64 dotatate injection)
8th septiembre 2020